About this trial
A single centre proof of concept study to assess whether Vitamin C improves the efficacy of Methenamine Hippurate (Hiprex®) in the prophylaxis of recurrent urinary tract infections (rUTIs) in women
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Female
Age ≥18 years
Recurrent proven UTI, defined as "two or more proven infections in six months or three or more infections in six months"
Willing and able to give fully informed consent
Disqualifiers
Males
Women who are pregnant or breast-feeding
Contraindications to methenamine hippurate as described in BNF: known allergy, gout, severe metabolic acidosis, severe dehydration, eGFR less than 10 ml/min, severe hepatic impairment
Currently using vitamin C containing supplement or cranberry extract tablets
Trial design
Sequential
Treatments tested in this trial
Methenamine Hippurate 1g BD
DrugMethenamine Hippurate 1g BD for 6 months
Methenamine Hippurate 1g BD + Vitamin C 1g BD
DrugMethenamine Hippurate 1g BD + Vitamin C 1g BD for 6 months
Treatment groups
Trial outcomes
Primary outcomes
Frequency of UTIs
The incidence of symptomatic UTI during each six-month treatment phase of either methenamine hippurate alone or methenamine hippurate plus vitamin C
Secondary outcomes
Urine pH
Measurement of urine pH during each treatment phase
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: